Clinical Trial Update: Ropeginterferon Alfa 2b for Early Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating Ropeginterferon Alfa 2b for early myelofibrosis; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Prefibrotic Stage of Myelofibrosis

Drugs mentioned

• Ropeginterferon alfa-2b (ropeginterferon alfa-2b)

Snippet

Sponsor: The University of Hong Kong | Conditions: Primary Myelofibrosis, Prefibrotic Stage, Myelofibrosis | Phase 2 | Status: UNKNOWN